title: [Multiple evanescent white dot syndrome and multiple sclerosis].
abstract: OBJECTIVE
  To describe a patient who fulfilled the criteria for both clinically definite multiple evanescent white dot syndrome (MEWDS) and multiple sclerosis.
  
  
  METHODS
  We performed a complete ophthalmologic and neurological examination in a 30-year-old woman who was referred to our department for blurred vision in her left eye (LE) with photopsia.
  
  
  RESULTS
  Following a complete ophthalmologic examination, the patient was diagnosed with MEWDS and coincident multiple sclerosis. She underwent therapy with intravenous methylprednisolone (1000 mg/day) for three days, followed by oral prednisone (1 mg/kg per day) for 15 days. Most of the symptoms and signs apparently regressed within one month, despite a still abnormal OCT macular scan, probably due to atrophic post-inflammatory changes in the outer and photoreceptor layers (rods and cones).
  
  
  CONCLUSIONS
  This report, showing the clinical features of MEWDS associated with multiple sclerosis, strongly suggests common neuropathological and inflammatory mechanisms between MS and white dot syndromes.
authors.affiliation: Service d'ophtalmologie, Policlinico Riuniti di Foggia, université de Foggia, Viale Pinto, 1, 71100 Foggia, Italie. giuseppe.querques@hotmail.it
authors.forename: G
authors.initials: G
authors.lastname: Querques
authors.forename: A V
authors.initials: AV
authors.lastname: Bux
authors.forename: R
authors.initials: R
authors.lastname: Forte
authors.forename: P
authors.initials: P
authors.lastname: Francesco
authors.forename: I
authors.initials: I
authors.lastname: Cristiana
authors.forename: N D
authors.initials: ND
authors.lastname: Noci
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001921:Brain / Q000473:pathology; D002825:Chorioretinitis / Q000175:diagnosis* / Q000188:drug therapy; D004172:Diplopia / Q000209:etiology; D004359:Drug Therapy, Combination; D004596:Electroretinography / Q000187:drug effects; D005074:Evoked Potentials, Visual / Q000187:drug effects / Q000502:physiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000008:administration & dosage; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy; D009902:Optic Neuritis / Q000175:diagnosis* / Q000188:drug therapy; D010211:Papilledema / Q000175:diagnosis / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage; D041623:Tomography, Optical Coherence; D058609:Visual Field Tests
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone; D008775:Methylprednisolone